



## *Life Sciences Licensing*

Recognized as a leading life sciences firm, WilmerHale has represented life sciences clients across the United States and the world for more than four decades. In the highly competitive landscape of life sciences, licensing transactions and establishing strategic alliances are critical. Our team helps clients protect their innovations, forge strategic alliances and successfully navigate a complex, dynamic industry. WilmerHale's experienced licensing lawyers shepherd biotech, pharmaceutical, healthcare and medical device clients of all sizes through the complex transactions that make their business possible. Backed by the deep well of knowledge possessed by the firm's patent, tax, antitrust and EU competition lawyers, our transactional lawyers are ready to handle even the most multifaceted matters.

### SELECT EXPERIENCE INCLUDES REPRESENTING:

- **Apellis Pharmaceuticals**, a clinical-stage biopharmaceutical company developing therapeutics, in a strategic collaboration with Swedish Orphan Biovitrum AB (Sobi) valued at up to \$1.25 billion to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need.
- **Arbor Biotechnologies**, developer of genomic tools designed to improve human health and sustainability, in its strategic research collaborations with TCR2 Therapeutics and Vertex Pharmaceuticals.
- **Autobahn Labs**, a virtual incubator partnering with top academic and research institutions, in a drug discovery partnership with the University of California San Diego to bring novel therapeutics to market, and in a strategic collaboration with the University of California San Francisco to identify promising early science.
- **Beam Therapeutics**, a biotechnology company developing precision genetic medicines through base editing, in its exclusive, four-year research collaboration with Pfizer.
- **Carisma Therapeutics**, a biopharmaceutical company, in a strategic collaboration agreement with Moderna Inc. to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for cancer treatment.

### PRACTICE AT A GLANCE

- Handle hundreds of complex strategic alliances, joint ventures, licensing and option transactions, including acquisition option and other M&A forms of technology acquisition transactions
- Significant client base ranging from biotechnology, pharmaceutical, diagnostic and medical device companies at all stages of growth to other key players in the space

- **D.E. Shaw Research**, providing research and development services to the biochemistry sector, in its exclusive license agreement with Eli Lilly for the development and commercialization of pharmaceutical products to treat immunological and inflammatory diseases.
- **Editas Medicine**, a leading gene editing company, in various strategic collaboration and licensing transaction, including its amended collaboration with Celgene Corporation, now a subsidiary of Bristol-Myers Squibb, to research, develop and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.
- **EQRx, Inc.**, a biopharmaceutical company committed to making innovative medicines at lower prices, in a global strategic partnership with CStone Pharmaceuticals.
- **Incyte Corporation**, a global biopharmaceutical company, in a collaboration and license agreement with MorphoSys to develop and commercialize anti-CD19 antibody tafasitamab.
- **Mersana Therapeutics**, a clinical-stage biopharmaceutical company focused on discovering and developing antibody-drug conjugates, in its global collaboration agreement with GSK.
- **Notch Therapeutics**, an immune cell therapy company, in a collaboration with Allogene Therapeutics to research and develop induced pluripotent stem cell-derived allogeneic therapies for hematologic cancer indications.
- **Novo Nordisk**, a multinational pharmaceutical company, in strategic collaborations with Dicerna Pharmaceuticals, Venture Therapeutics and Flagship Pioneering.
- **PTC Therapeutics**, a biopharmaceutical company focused on discovering, developing and commercializing medicine for patients with rare diseases, in a financing agreement to monetize a portion of the risdiplam royalty stream for \$650 million from Royalty Pharma plc.
- **Repare Therapeutics**, a precision oncology company, in strategic research collaborations with Bristol-Myers Squibb and Roche.
- **Ribometrix**, a company specializing in RNA-based therapeutics, in a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets.
- **Verve Therapeutics**, a biotechnology company pioneering a new approach to the care of cardiovascular disease, in its exclusive, four-year global research collaboration with Vertex Pharmaceuticals.
- **Voyager Therapeutics**, a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, in its strategic collaborations with AbbVie, Neurocrine Biosciences, Pfizer, Novartis and Roche.

For more information, please contact:

**Steven D. Barrett** — Partner | +1 617 526 6238 | [steven.barrett@wilmerhale.com](mailto:steven.barrett@wilmerhale.com)  
**Sarah Hogan** — Partner | +1 617 526 6706 | [sarah.hogan@wilmerhale.com](mailto:sarah.hogan@wilmerhale.com)  
**Jenna Ventrino** — Partner | +1 617 526 6351 | [jenna.ventorino@wilmerhale.com](mailto:jenna.ventorino@wilmerhale.com)

Guide clients in all aspects of licensing intellectual property and establishing strategic alliances, including:

- Collaboration agreements
- Co-development agreements
- Commercialization agreements
- Material transfer agreements
- Manufacturing and supply agreements
- Clinical trial agreements
- Confidentiality agreements
- Distribution agreements
- University licensing agreements



**WilmerHale's life sciences practice has been ranked by Chambers USA in the first tier every year since 2008**



**LMG Life Sciences named WilmerHale US Life Cycle Firm of the Year in 2017 and among the shortlist from 2012–2023**



**The Legal 500 US ranked WilmerHale among the top law firms for life sciences from 2013–2023**